Metabolic Disturbances in Psychiatric Disorder: The Question of Diagnostic Specificity

  • Csaba M. Banki
  • Mihály Arató
  • Zsuza Papp


An increasing number of indirect neurochemical markers have been proposed to reflect CNS biological dysfunctions underlying some psychiatric disorders in man. CSF amine metabolites were often reported to be decreased in depression, but several later studies contradicted; there are some excellent reviews covering this subject1,2. In contrast, more recent works seem to support the view that CSF biochemical parameters /concentration of HVA, 5HIAA, MHPG, etc./ are more closely correlated with syndrome subtypes, symptoms or other physical or psychological variables than with the clinical diagnosis itself3-5. Some “elementary” symptoms were already found to be related to certain CSF metabolites: motor activity to HVA6, anxiety and insomnia to 5HIAA7, suicide and aggression to 5HIAA and MHPG2,8,9. However, the study of isolated symptoms in relationship with biochemical alterations has usually been confined to a limited number of clinical disorders4,10.


Alcohol Dependence Suicidal Thought Adjustment Disorder Amine Metabolite Comprehensive Psychopathological Rating Scale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H.M. Van Praag, “Depression and Schizophrenia, a Contribution on their Chemical Pathologies.” Spectrum, New York /1977/Google Scholar
  2. 2.
    M. Asberg, and L. Bertilsson, Serotonin in depressive illness, studies of CSF 5KIAA, in: “Neuro-Psychopharmacology,” B. Saletu, P. Berner, L.E. Hollister, eds., Pergamon, Oxford /1979/Google Scholar
  3. 3.
    C.M. Banki, G. Molnar, I. Fekete, Correlation of individual symptoms and other clinical variables with CSF amine metabolites and tryptophan in depression. Arch.Psychiat,Nervenkr. 229:345 /1981/PubMedCrossRefGoogle Scholar
  4. 4.
    H. Agren, Biological markers in major depressive disorders. Thesis, Uppsala /1981/Google Scholar
  5. 5.
    M. Asberg, L. Bertilsson, E. Rydin, D. Schalling, P. Thoren, and L. Traskman, Monoamine metabolites in CSF in relation to depressive illness, suicidal behaviour and personality, in: “Recent Advances in Neuro-Psychopharmacclogy,” B. Angrist, G.D. Burrows, M. Lader, O. Lingjoerde, G. Sedrau, D. Wheatley, eds., Pergamon, Oxford /1981/Google Scholar
  6. 6.
    H.M. Van Praag, J.P.W. Lakke, and T. Schut, Dopamine metabolism in depression, psychoses, Parkinson disease, the problem of specificity of biological variables in behavioural disorders. Psychol.Med. 5:138 /1975/PubMedCrossRefGoogle Scholar
  7. 7.
    C.M. Banki, Correlation of anxiety and related symptoms with CSF 5HIAA in depressed women. J.Neur.Transmiss. 41:135 /1977/CrossRefGoogle Scholar
  8. 8.
    G.L. Brown, J.C. Ballenger, M.D. Minichiello, and P.K. Goodwin, Human aggression and its relationship to cerebrospinal fluid 5HIAA, MHPG and HVA, in: “Psychopharmacology of Aggression,” M. Sandler, ed, Raven, New York /1979/Google Scholar
  9. 9.
    C.M. Banki, and M. Arato, Amine metabolites and neuroendocrine responses related to depression and suicide J.Affect,Disord /in. press/Google Scholar
  10. 10.
    C.M. Banki, Evidence of disturbance of monoamines in depression, in: “Management of Depression with Monoamine Precursors,” H.M. Van Rraag, J. Mendlewitz, eds., Karger, Basel /in press/Google Scholar
  11. 11.
    G. Curzon., B.D. Kantamaneni, P.Van Boxel, and P.K. Gillman, Substances related to serotonin in plasma and in lumbar and ventricular fluids of psychiatric patients. Acta psychiat. scand. suppl. 280:3 /1980/Google Scholar
  12. 12.
    B.J. Carroll, The dexamethasone suppression test for melancholia. Brit.J.Psychiat. 140:292 /1982/PubMedCrossRefGoogle Scholar
  13. 13.
    D. C. Jimerson, R.M. Post, D. P. Van Kammen, J.S. Skyler, G.L. Brown, and W.E. Bunney, CSF Cortisol levels in depression and schizophrenia. Amer.J.Psychiat. 137:979 /1980/PubMedGoogle Scholar
  14. 14.
    M. Asberg, S.A. Montgomery, C. Perris, D. Schalling, and G. Sedvall, A comprehensive psychopathological rating scale. Acta psychiat. scand. suppl. 271:5 /1978/CrossRefGoogle Scholar
  15. 15.
    W.F. Gattaz, P. Waldmeier, and H. Beckmann, CSF monoamine metabolites in, schizophrenic patients. Acta psychiat.scan.d. 66:350 /1982/CrossRefGoogle Scholar
  16. 16.
    H. Beckmann, Die medikametöse Therapie der Depression, Nervenarzt 52:135 /1981/PubMedGoogle Scholar
  17. 17.
    E. Ryditi, D. Schalling, and M. Asberg, Rorschach ratings in. depressed and suicidal patients with low levels of 5HIAA in. cerebrospinal fluid. Psychiat. Res. 7:229 /1982/CrossRefGoogle Scholar
  18. 18.
    K.L. Benson, V.P. Zarcone, K.F. Faull, J.D. Barchas, P.A. Berger, REM sleep eye movement activity and CSF concentration, of 5 HI A A in pscchiatric patients. Psychiat.Res. 8:73 /1983/CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Csaba M. Banki
    • 1
  • Mihály Arató
    • 2
  • Zsuza Papp
    • 3
  1. 1.Regional Neuropsychiatric HospitalNagykállóHungary
  2. 2.Hamilton Psychiatric HospitalOntarioCanada
  3. 3.National Institute for Nervous and Mental DiseasesBudapestHungary

Personalised recommendations